SEC Form 4 · accession 0001193125-26-349537
Damora Therapeutics, Inc. · DMRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Cheng
Director
Period of report
Aug 12, 2026
Accepted (ET)
Aug 13, 2026 · 5:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001800315
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $31.00 | Aug 12, 2026 | A | 30,350 | A | — | Aug 12, 2036 | Ordinary Shares | 30,350 | 30,350 | D |
Explanation of responses
- F1This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.